This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Center For Disease Control Survey Reports That One In Four Women Choose Permanent Birth Control

According to the recently released 2006-08 National Survey of Family Growth by the Center for Disease Control (CDC), one in four women choose permanent birth control. Conceptus, Inc. (NASDAQ:CPTS) wants women to know that its Essure ® permanent birth control procedure has been gaining in popularity, and is a safe and effective solution used by hundreds of thousands of women worldwide.

In the past, tubal ligation – a surgery that requires cutting into the body, general anesthesia and a hospital stay – was the only permanent birth control option available to women. Since 2002, the Essure permanent birth control procedure has been a solution to this invasive surgery, and many women have chosen Essure over tubal ligation. The Essure procedure can be performed in the comfort of a doctor’s office in minutes; it does not require surgery, general anesthesia, scarring, burning, hormones or slowing down to recover.

Female permanent birth control is used by 16.7%, or 10.3 million women, and male sterilization (vasectomy) is used by the partners of 6.1%, or 3.7 million women.

“From the CDC data, we can infer that when combined, permanent birth control for both men and women is the single most prevalent form of birth control used today,” said Mark Sieczkarek, CEO of Conceptus, Inc.

“When a woman is considering permanent birth control I recommend the Essure procedure," said Dr. Cindy Basinski, a board-certified OB/GYN based in Evansville, Ind. "Women need to be informed about their options, and I'm always glad to bring Essure to their attention. It is proven, easy, and extremely effective. And since it can be performed without anesthesia, Essure allows patients to get back to their family and normal routine quickly.”

Since receiving FDA approval in 2002, the Essure procedure has become a trusted solution for more than 435,000 women and their physicians. The Essure procedure is 99.80 percent effective with zero pregnancies reported in four years of clinical trials, making it the most effective permanent birth control available. To learn more about Essure please visit Essure.com. The National Survey of Family Growth can be found here:  http://www.cdc.gov/nchs/nsfg.htm.

About the Essure Procedure:

The Essure procedure, FDA approved since 2002, is a proven, hormone-free permanent birth control procedure that can be performed in the comfort of a physician’s office in less than 10 minutes without surgery, burning, anesthesia or the risks associated with tubal ligation. Small, flexible inserts are placed in a woman’s fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around the micro-inserts to prevent sperm from reaching the egg. Essure is 99.80% effective based on four years of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor’s office the cost may be as low as a simple co-pay.

Three months after the Essure procedure, a doctor performs an Essure Confirmation Test to confirm both that the inserts are in place and the fallopian tubes are fully blocked, and that the patient can rely on Essure for permanent birth control. Essure has been proven and trusted by physicians since 2002, with more than 435,000 women worldwide having undergone the Essure procedure.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,655.52 +298.65 1.72%
S&P 500 2,047.63 +34.74 1.73%
NASDAQ 4,730.4950 +86.1830 1.86%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs